Patents by Inventor Gilles Doerflinger

Gilles Doerflinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them
    Publication number: 20050165005
    Abstract: The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH2, ORc, SRc, SORa, SO2Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSO2Ra, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF3, CHF2, CH2F, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.
    Type: Application
    Filed: November 24, 2004
    Publication date: July 28, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Arielle Genevois-Borella, Jean-Luc Malleron, Jean Bouquerel, Gilles Doerflinger, Andrees Bohme, Gaetan Touyer, Jean-Francois Sabuco, Corrine Terrier, Serge Mignani, Michel Evers, Youssef El-Ahmad
  • Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
    Publication number: 20050131012
    Abstract: The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 16, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: William Metz, Frank Halley, Gilles Dutruc-Rosset, Yong Choi-Sledeski, Gregory Bernard Poli, David Fink, Gilles Doerflinger, Bao-Guo Huang, Ann Gelormini, Juan Gamboa, Andrew Giovanni, Joachim Roehr, Joseph Tsay, Fernando Camacho, William Hurst, Stephen Harnish, Yulin Chiang
  • Triazine derivatives and their application as antitelomerase agents
    Patent number: 6887873
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-François Riou, Gilles Doerflinger, Jean-Louis Mergny, François Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070571
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: November 19, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdekazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070575
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 30, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 6858608
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
    Publication number: 20050026984
    Abstract: The present invention relates in particular to novel chemical compounds, particularly novel substituted thieno[2,3-c]pyrazoles, to the compositions containing them and to their use as medicinal products for treating cancers and also neurodegenerative diseases.
    Type: Application
    Filed: July 28, 2004
    Publication date: February 3, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Antony Bigot, Francois Clerc, Gilles Doerflinger, Serge Mignani, Herve Minoux
  • Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
    Publication number: 20050014758
    Abstract: The present invention discloses and claims compounds of formula I and their pharmaceutically acceptable salts, and methods of using said compounds of formula I, either alone or in combination with other medicaments, as antiarrhythmic medicaments with a cardioprotective component for prophylaxis or treatment of infarction, for the treatment of angina pectoris, and as inhibitors of pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure. Pharmaceutical compositions comprising compounds of formula I or compounds of formula I in combination with one or more other medicaments and processes for the preparation of compounds of formula I are also disclosed and claimed.
    Type: Application
    Filed: June 10, 2004
    Publication date: January 20, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Jean-Christophe Carry, Gilles Doerflinger, Arielle Genevois-Borella, Michel Evers, Alain Le Brun, Jean-Paul Martin, Pascal Desmazeau, Serge Mignani, Heinz-Werner Kleemann
  • Streptogramin derivatives, preparation method and compositions containing same
    Publication number: 20040266667
    Abstract: Group B streptogramin derivatives of general formula (I) are disclosed: 1
    Type: Application
    Filed: March 2, 2004
    Publication date: December 30, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Pascal Desmazeau, Gilles Doerflinger, Yves Ribeill, Eric Bacque, Jean-Claude Barriere, Gilles Dutruc-Rosset, Gerard Puchault
  • Chemical derivatives and their application as antitelomerease agent
    Publication number: 20030087931
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: March 25, 2002
    Publication date: May 8, 2003
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030078263
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: January 9, 2002
    Publication date: April 24, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Streptogramin derivatives, their preparation and compositions containing them
    Patent number: 6541451
    Abstract: B-Group streptogramin compounds of formula (I): are useful as antimicrobial agents, optionally combined with at least one A-group streptogramin compound.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: April 1, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Eric Bacque, Jean-Claude Barriere, Gilles Doerflinger, Gilles Dutruc-Rosset, Guy Pantel
  • Streptogramin derivatives, preparation method and compositions containing same
    Publication number: 20020151676
    Abstract: Group B streptogramin derivatives of general formula (I): 1
    Type: Application
    Filed: June 5, 2002
    Publication date: October 17, 2002
    Applicant: Aventis Pharma S.A.
    Inventors: Pascal Desmazeau, Gilles Doerflinger, Yves Ribeill, Eric Bacque, Jean-Claude Barriere, Gilles Dutruc-Rosset, Gerard Puchault